Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Gastrointestinal Tumors
Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic…
- Trial name
- NCT05981235
- Testing
- AZD6422 CLDN18.2 CAR-T product
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Peking University
Multiple Myeloma
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT06705725
- Testing
- CBG002 CAR-T Cell Suspension
- Volunteers
- 38 people
- Sponsor
- Carbiogene Therapeutics Co. Ltd.
Relapsed or Refractory Multiple Myeloma (RRMM)
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - GPRC5D CAR-T cell therapy.
- Trial name
- NCT07003568
- Testing
- Dual-targeting BCMA-GPRC5D CAR-T cell infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital
Leukemia, Lymphoma
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies.
- Trial name
- NCT03121625
- Testing
- Autologous CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Solid Tumors
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with ALPP-positive Advanced Solid Tumors.
- Trial name
- NCT04627740
- Testing
- Retroviral vector-transduced autologous T cells to express anti-ALPP CARs
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xinqiao Hospital of Chongqing
Hemopathy
Real-life Management of Patients Eligible for CAR-T Cell Therapy
Adoptive immunotherapy using CAR-T cells is now one of the Advanced Therapy Medicines routinely used for relapsed or refractory lymphoid hemopathies.
- Trial name
- CARAVAGE (NCT06369389)
- Testing
- Patients eligible for CAR-T treatment
- Where
- France
- Volunteers
- 550 people
- Sponsor
- University Hospital, Toulouse
Alveolar Soft Part Sarcoma
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)
CLIC-YYC-GPNMB-02 is a Single Patient Study (SPS) developed according to the Health Canada template and guidelines released in 2019 for studies to access therapies not otherwise available to patients, in the situation where there…
- Trial name
- NCT06789081
- Testing
- GCAR1
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- AHS Cancer Control Alberta
Hematopathology Eligible or CAR-t Cell Treatment
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
- Trial name
- NCT04328298
- Where
- 36 sites in France
- Volunteers
- 5,000 people
- Sponsor
- The Lymphoma Academic Research Organisation
CRC (Colorectal Cancer), Metastatic Colorectal Cancer
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer.
- Trial name
- Wondercel-UWD1 (NCT06653010)
- Testing
- Universal CAR-T cells injection for treating mCRC
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Lung Squamous Cell Carcinoma
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
The purpose of this study is to observe and confirm the safety, tolerance and cell pharmacokinetics of lentivirus-transduced CAR-GPC3 T cells (CAR-GPC3 T cells targeting GPC3)
- Trial name
- NCT02876978
- Testing
- CAR-GPC3 T Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Gastric Cancer, Pancreatic Cancer
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT06134960
- Testing
- KD-496
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University
Solid Tumor
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT05373147
- Testing
- αPD1-MSLN-CAR T cells
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Mengchao Cancer Hospital
B Acute Lymphoblastic Leukemia, CD19 Positive
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy and NKTR-255, and to see how well they work in treating patients with CD19 positive B acute…
- Conditions
- B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
- Trial name
- NCT03233854
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Stanford University
Immunotherapy
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
This is an experimental study to evaluate the safety and efficacy of CAR T cells targeting CAIX in the treatment of advanced renal cancer.
- Trial name
- NCT04969354
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
T1DM - Type 1 Diabetes Mellitus
Allogeneic Anti-CD7 CAR-T for Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency and lifelong dependence on exogenous insulin.
- Trial name
- NCT07528105
- Testing
- Allogeneic CD7-Targeted CAR-T Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Sclerosis (MS), Myasthenia Gravis (MG)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
- Trial name
- NCT07676266
- Testing
- CD20/BCMA-directed CAR-T cells Autologous 2nd generation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Solid Tumor
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant…
- Trial name
- NCT05775666
- Testing
- UCLM802 Cell Injection
- Volunteers
- 87 people
- Sponsor
- Peking University
Mantle Cell Lymphoma
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
This is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.
- Trial name
- NCT07453095
- Testing
- Glofitamab
- Where
- 14 sites in Italy
- Volunteers
- 41 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Acute Myeloid Leukemia
AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells
AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality.
- Trial name
- CAR-LAM (NCT04169022)
- Testing
- Sample collection
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
HIV/AIDS
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist…
- Trial name
- NCT03240328
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangzhou 8th People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.